Novartis To Invest $35M In Gamida Cell With Option For Acquisiton

August 19, 2014 | According to a “Globes” report, Israeli stem cell technologies developer Gamida Cell has confirmed reports of signing an investment and options agreement with Novartis Pharma AG. In the terms of the agreement, Novartis will invest $35 million in Gamida Cell and in return will receive 15 percent equity and the option to fully acquire the company. The agreement remains dependent, however, on the achievement of certain milestones, such as the development of NiCord for the treatment of blood cancers like leukemia and lymphoma.